Epoch 47: Is the Biotech Valuation Reset Complete?
Valuation Trends & The Importance of Time to Catalyst post-IPO
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary is as always on Thursday focused on the general market update. For the week XBI was DOWN -2% and remains green at +7% for the year. In today’s newsletter, we dive into the latest trends and challenges in the biotech and venture funding landscape. From Seed to Series C, compa…
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.